Cecilia Jones Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

Cecilia Jones is Chief Financial Officer of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 37,394 shares of AGIO, which is worth approximately $1.63 Million. The most recent transaction as insider was on Dec 30, 2025, when has been sold 2,932 shares (Common Stock) at a price of $27.09 per share, resulting in proceeds of $79,427. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 37.4K

10.4% 3M change

85.5% 12M change

Total Value Held $1.63 Million

Cecilia Jones Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 30 2025	SELL Open market or private sale	$79,427 $27.09 p/Share	2,932 Reduced 7.27%	37,394 Common Stock
Dec 30 2025	BUY Exercise of conversion of derivative security	-	6,000 Added 12.95%	40,326 Common Stock
Sep 26 2025	SELL Open market or private sale	$134,247 $36.77 p/Share	3,651 Reduced 9.73%	33,870 Common Stock
Sep 26 2025	BUY Exercise of conversion of derivative security	-	7,472 Added 16.61%	37,521 Common Stock
Jun 24 2025	SELL Open market or private sale	$59,701 $33.54 p/Share	1,780 Reduced 5.59%	30,049 Common Stock
Jun 24 2025	BUY Exercise of conversion of derivative security	-	6,000 Added 15.86%	31,829 Common Stock
Mar 03 2025	SELL Open market or private sale	$80,853 $35.54 p/Share	2,275 Reduced 8.09%	25,829 Common Stock

Mar 01 2025	BUY Exercise of conversion of derivative security	-	7,667 Added 21.8%	27,510 Common Stock
Sep 26 2024	SELL Open market or private sale	$124,634 $49.03 p/Share	2,542 Reduced 11.2%	20,158 Common Stock
Sep 26 2024	BUY Exercise of conversion of derivative security	-	7,473 Added 24.77%	22,700 Common Stock
Mar 05 2024	SELL Open market or private sale	$21,887 $32.57 p/Share	672 Reduced 4.33%	14,840 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	2,000 Added 11.42%	15,512 Common Stock
Jan 24 2024	SELL Open market or private sale	$40,813 $21.64 p/Share	1,886 Reduced 12.61%	13,069 Common Stock
Jan 20 2024	BUY Exercise of conversion of derivative security	-	5,380 Added 26.46%	14,955 Common Stock
Sep 28 2023	SELL Open market or private sale	$54,017 $24.79 p/Share	2,179 Reduced 18.54%	9,575 Common Stock
Sep 26 2023	BUY Exercise of conversion of derivative security	-	7,472 Added 38.86%	11,754 Common Stock
Jun 30 2023	SELL Open market or private sale	$45,290 $28.36 p/Share	1,597 Reduced 29.68%	3,783 Common Stock
Jun 28 2023	BUY Exercise of conversion of derivative security	-	5,380 Added 50.0%	5,380 Common Stock

Also insider at

LOGC

LogicBio Therapeutics, Inc. Healthcare

Chief Financial Officer

Cecilia Jones

Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Value

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

Operation

Value

Type

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Track Activities on AGIO

Account